SOURCE: Industrial Info Resources

Industrial Info Resources

January 19, 2015 06:15 ET

If It's Planned, Will They Build It? How Many Pharma-Biotech Capital Projects Actually Make Construction? -- An Industrial Info News Alert

SUGAR LAND, TX--(Marketwired - Jan 19, 2015) - Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- When considering the Pharmaceutical-Biotech Industry's reported capital project spending for any given year, it is important to analyze the projects after they are first reported. Utilizing analysis tools, such as Gap Measurement and Project Fallout, help to illuminate an accurate view of project-spending patterns. From 2012-14, 71% of reported pharma-biotech projects in a given year made it to construction.

Within this article: Outlook for cash-intensive projects in the Pharmaceutical-Biotech Industry.

For details, view the entire article by subscribing to Industrial Info's Premium Industry News, or browse other breaking industrial news stories at

Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, three offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle™, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. To contact an office in your area, visit the "Contact Us" page.

Contact Information

  • Contact:
    William Ploch